Time filter

Source Type

Patent
Laboratorios Del Dr. Esteve S.A. | Date: 2016-08-09

The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.


Patent
Laboratorios Del Dr. Esteve S.A. | Date: 2017-04-26

The present invention relates to oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib, processes for preparation of the same and their use as medicaments, more particularly for the treatment of pain.


The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.


Patent
Laboratorios del Dr. Esteve S.A. | Date: 2017-05-10

The present invention relates to new tricyclic triazolic compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.


Patent
Laboratorios del Dr. Esteve S.A. | Date: 2017-03-22

The present invention provides new adenoassociated virus vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidoses Type IIIB.


The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma () receptor, and the -opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.


The present invention relates to compounds having dual pharmacological activity towards both the sigma () receptor, and the -opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.


The present invention relates to compounds having dual pharmacological activity towards both the sigma () receptor, and the -opioid receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain. (formula 1) wherein Y is (formula 2) or (formula 3) n is 1 or 2; q is 1, 2, 3, 4, 5 or 6; X is a bond, -C(O)O-, -C(0)NR 8-, -C(O)-, -0- or -C(R 4R 4.)-; R 1is C(0)R 5or S(O) 2R 5.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.2.1-5 | Award Amount: 8.54M | Year: 2014

Neuropathic pain has a high incidence in Europe and often affects the patients emotional balance and quality of life. Recent meta-analyses have shown that conventional analgesic drugs are not sufficiently effective in these patients and are limited by serious side effects. The search for new analgesics is extremely difficult despite identification of several new potential targets and enormous investment by the pharmaceutical industry. Important reasons for this failure are the poor predictive validity of currently available animal models of chronic pain, that do not simulate multidimensional clinical pain, and the high inter-individual variability of neuropathic pain manifestations and treatment responses. We will overcome these obstacles by an interdisciplinary collaboration between basic science groups, clinicians and leading private companies. This consortium will validate new animal models to evaluate the electrophysiological, behavioural, emotional and cognitive manifestations of neuropathic pain and the effectiveness of novel compounds. The use of these models in combination with other behavioural paradigms and new conditional knockout mouse lines for specific components of the endogenous opioid and cannabinoid system will permit the identification of novel druggable targets and biomarkers for neuropathic pain. Novel analgesic compounds acting on these endogenous systems developed by the private companies of the consortium will be tested in these new paradigms. Clinical studies will identify novel biomarkers for neuropathic pain using powerful genetics approaches and investigate treatment effectiveness with a translational focus based on cross validation of the findings in animals and humans.


Patent
Laboratorios Del Dr. Esteve S.A. | Date: 2016-07-12

The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Loading Laboratorios Del Dr. Esteve SA collaborators
Loading Laboratorios Del Dr. Esteve SA collaborators